Lantheus Holdings, Inc. (NASDAQ:LNTH) Sees Significant Decline in Short Interest

Lantheus Holdings, Inc. (NASDAQ:LNTH - Get Free Report) was the recipient of a significant decline in short interest during the month of February. As of February 28th, there was short interest totalling 6,340,000 shares, a decline of 13.3% from the February 13th total of 7,310,000 shares. Based on an average daily trading volume, of 902,000 shares, the days-to-cover ratio is currently 7.0 days. Approximately 9.5% of the shares of the stock are sold short.

Analyst Ratings Changes

Several analysts recently weighed in on the stock. The Goldman Sachs Group began coverage on shares of Lantheus in a research note on Wednesday, December 18th. They issued a "buy" rating and a $143.00 price objective on the stock. Truist Financial increased their price target on Lantheus from $120.00 to $127.00 and gave the company a "buy" rating in a research note on Thursday, February 27th. JMP Securities restated a "market outperform" rating and set a $112.00 price objective on shares of Lantheus in a research report on Tuesday, January 14th. Finally, B. Riley reduced their target price on Lantheus from $127.00 to $122.00 and set a "buy" rating on the stock in a report on Friday. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, Lantheus has an average rating of "Moderate Buy" and a consensus target price of $129.43.

Lantheus Price Performance

Shares of Lantheus stock traded down $1.14 on Friday, hitting $97.71. 1,069,481 shares of the company's stock traded hands, compared to its average volume of 936,960. The company has a fifty day moving average of $92.67 and a two-hundred day moving average of $96.51. Lantheus has a one year low of $57.92 and a one year high of $126.89. The company has a market capitalization of $6.69 billion, a price-to-earnings ratio of 16.26 and a beta of 0.38.

Remove Ads

Lantheus (NASDAQ:LNTH - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.57 by ($0.23). Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The business had revenue of $391.11 million for the quarter, compared to the consensus estimate of $376.61 million. Equities research analysts anticipate that Lantheus will post 6.01 earnings per share for the current year.

Insiders Place Their Bets

In other news, CFO Robert J. Jr. Marshall sold 10,000 shares of Lantheus stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the sale, the chief financial officer now directly owns 113,860 shares of the company's stock, valued at approximately $11,445,207.20. This trade represents a 8.07 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Mary Anne Heino sold 53,107 shares of the company's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $94.35, for a total value of $5,010,645.45. Following the completion of the transaction, the director now directly owns 440,399 shares of the company's stock, valued at $41,551,645.65. This represents a 10.76 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 64,109 shares of company stock valued at $6,110,806. 1.50% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Lantheus

Several institutional investors have recently made changes to their positions in the stock. Atria Investments Inc bought a new stake in Lantheus in the 3rd quarter valued at about $330,000. Sumitomo Mitsui Trust Group Inc. bought a new stake in shares of Lantheus during the third quarter valued at approximately $728,000. Victory Capital Management Inc. raised its position in shares of Lantheus by 198.9% during the third quarter. Victory Capital Management Inc. now owns 76,833 shares of the medical equipment provider's stock worth $8,432,000 after purchasing an additional 51,128 shares during the period. CIBC Asset Management Inc acquired a new position in shares of Lantheus during the third quarter worth approximately $222,000. Finally, Natixis Advisors LLC lifted its holdings in shares of Lantheus by 8.2% in the 3rd quarter. Natixis Advisors LLC now owns 46,445 shares of the medical equipment provider's stock worth $5,097,000 after purchasing an additional 3,516 shares in the last quarter. Institutional investors and hedge funds own 99.06% of the company's stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.